Liver and gastrointestinal first-pass effects of azosemide in rats

被引:35
作者
Kim, J [1 ]
Kim, SH [1 ]
Lee, MG [1 ]
机构
[1] SEOUL NATL UNIV, COLL PHARM, SEOUL 151742, SOUTH KOREA
关键词
D O I
10.1111/j.2042-7158.1997.tb06129.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since considerable first-pass effects of azosemide have been reported after oral administration of the drug to rats and man, first-pass effects of azosemide were evaluated after intravenous, intraportal and oral administration, and intraduodenal instillation of the drug, to rats. The total body clearances of azosemide after intravenous (5 mg kg(-1)) and intraportal (5 and 10 mg kg(-1)) administration of the drug to rats were considerably smaller than the cardiac output of rats suggesting that the lung or heart first-pass effect (or both) of azosemide after oral administration of the drug to rats was negligible. The total area under the plasma concentration-time curve from time zero to time infinity (AUC) after intraportal administration (5 mg kg(-1)) of the drug was significantly lower than that after intravenous administration (5 mg kg(-1)) of the drug (1000 vs 1270 pg min mt) suggesting that the liver first-pass effect of azosemide was approximately 20% in rats. The AUC from time 0 to 8 h (AUC(0-8 h)) after oral administration (5 mg kg(-1)) of the drug was considerably smaller than that after intraportal administration (5 mg kg(-1)) of the drug (27.1 vs 1580 mu g min mL(-1)) suggesting that there are considerable gastrointestinal first-pass effects of azosemide after oral administration of azosemide to rats. Although the AUC(0-8 h), after oral administration (5 mg kg(-1)) of azosemide was approximately 15% lower than that after intraduodenal instillation (5 mg kg(-1)) of the drug (27.1 vs 32.0 mu g min mL(-1)), the difference was not significant, suggesting that the gastric first-pass effect of azosemide was not considerable in rats. Azosemide was stable in human gastric juices and pH solutions ranging from 2 to 13. Almost complete absorption of azosemide from whole gastrointestinal tract was observed after oral administration of the drug to rats. The above data indicated that most of the orally administered azosemide disappeared (mainly due to metabolism) following intestinal first-pass in rats.
引用
收藏
页码:878 / 883
页数:6
相关论文
共 16 条
[1]   DISPOSITION OF AZOSEMIDE .1. DISTRIBUTION, METABOLISM AND EXCRETION FOLLOWING INTRAVENOUS ADMINISTRATION TO RATS [J].
ASANO, T ;
INOUE, T ;
KURONO, M .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1984, 104 (11) :1181-1190
[2]  
BRATER CD, 1979, CLIN PHARMACOL THER, V25, P435
[3]   AZOSEMIDE KINETICS AND DYNAMICS [J].
BRATER, DC ;
DAY, B ;
ANDERSON, S ;
SEIWELL, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (04) :454-458
[4]   NEW CALCULATION METHOD OF MEAN TOTAL-BODY CLEARANCE OF DRUGS AND ITS APPLICATION TO DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (01) :90-91
[5]   NEW CALCULATION METHOD FOR MEAN APPARENT DRUG VOLUME OF DISTRIBUTION AND APPLICATION TO RATIONAL DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1067-1069
[6]   CRITICAL EVALUATION OF THE POTENTIAL ERROR IN PHARMACOKINETIC STUDIES OF USING THE LINEAR TRAPEZOIDAL RULE METHOD FOR THE CALCULATION OF THE AREA UNDER THE PLASMA LEVEL TIME CURVE [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06) :539-546
[7]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[8]   PHARMACOKINETICS OF DIAZEPAM FOLLOWING MULTIPLE-DOSE ORAL-ADMINISTRATION TO HEALTHY HUMAN SUBJECTS [J].
EATMAN, FB ;
COLBURN, WA ;
BOXENBAUM, HG ;
POSMANTER, HN ;
WEINFELD, RE ;
RONFELD, R ;
WEISSMAN, L ;
MOORE, JD ;
GIBALDI, M ;
KAPLAN, SA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05) :481-494
[9]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[10]   CLINICAL AND PHARMACOLOGICAL INVESTIGATIONS OF NEW SALURETIC AZOSEMID [J].
KRUCK, F ;
BABLOK, W ;
BESENFELDER, E ;
BETZIEN, G ;
KAUFMANN, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 14 (03) :153-161